How should I manage bridging therapy with enoxaparin (Clexane) and acenocoumarol (Acitrom), including dose adjustments and INR monitoring?

Bridging Therapy with Enoxaparin (Clexane) and Acenocoumarol (Acitrom): Dosing and Monitoring Protocol

Start enoxaparin at 1 mg/kg subcutaneously every 12 hours (or 1.5 mg/kg once daily) when INR falls below 2.0, continue until INR reaches therapeutic range (2.0-3.0) on two consecutive days, then discontinue enoxaparin while maintaining acenocoumarol. This approach is supported by multiple clinical trials demonstrating safety and efficacy in bridging anticoagulation 1.

Initial Bridging Strategy

When to Start Enoxaparin

• Begin bridging when acenocoumarol is interrupted and INR drops below 2.0
• For planned procedures: Stop acenocoumarol 5-7 days before surgery
• Start enoxaparin when INR <2.0 (typically 2-3 days after stopping acenocoumarol) 1

Enoxaparin Dosing Based on Thrombotic Risk

High Thrombotic Risk Patients (mechanical mitral valve, recent VTE <3 months, antiphospholipid syndrome):

• 1 mg/kg subcutaneously every 12 hours 1
• Alternative: 1.5 mg/kg once daily 1
• Last preoperative dose: Give half the daily dose on the morning 24 hours before procedure 2

Moderate Thrombotic Risk Patients (atrial fibrillation with CHA₂DS₂-VASc ≥4, VTE >3 months ago):

• 1 mg/kg subcutaneously once daily 3, 4
• Consider half-therapeutic dosing (0.5 mg/kg twice daily) for intermediate risk 5

Low Thrombotic Risk (CHA₂DS₂-VASc <4, remote VTE):

• Prophylactic dosing: 40 mg once daily 6
• Consider no bridging - evidence shows minimal benefit and increased bleeding risk 7

Critical Dose Adjustments

Renal Insufficiency (CrCl <30 mL/min):

• Reduce to 1 mg/kg once daily instead of twice daily 8
• Monitor anti-Xa levels if available (target 0.5-1.0 IU/mL for therapeutic dosing) 9

Obesity (BMI ≥40 kg/m²):

• Use actual body weight for dosing
• Standard 1 mg/kg dosing remains appropriate 9

Elderly (≥75 years):

• Use standard weight-based dosing but monitor closely for bleeding 6

Acenocoumarol (Acitrom) Management

Stopping Before Procedure

• Discontinue 5-7 days before surgery (acenocoumarol has shorter half-life than warfarin)
• Check INR 1-2 days before procedure to confirm <1.5 2

Restarting After Procedure

Timing:

• Low bleeding risk procedures: Resume acenocoumarol evening of procedure (day 0) at usual maintenance dose 2
• High bleeding risk procedures: Resume 24-72 hours post-procedure (day 1-3) 2

Initial Dosing:

• Restart at patient's usual maintenance dose (typically 2-4 mg daily for acenocoumarol) 1
• Do NOT use loading doses - increases bleeding risk without faster therapeutic effect

INR Monitoring Protocol

Pre-Procedure Monitoring

• Check INR 1-2 days before procedure to confirm <1.5 for safe surgery 2
• If INR >1.5: delay procedure or give vitamin K 1-2.5 mg orally

Post-Procedure Monitoring

Days 1-3:

• Check INR daily while on enoxaparin bridging
• Continue enoxaparin until INR ≥2.0

Days 4-7:

• Check INR every 1-2 days until stable in therapeutic range
• Enoxaparin should overlap with acenocoumarol for minimum 5 days AND until INR ≥2.0 on two consecutive measurements 6, 1

After Therapeutic INR Achieved:

• Check INR 2-3 times weekly for first 2 weeks
• Then weekly for 1 month
• Then monthly once stable

Discontinuing Enoxaparin

Stop enoxaparin when BOTH criteria met:

1. INR ≥2.0 (or patient's target range)
2. Therapeutic INR documented on two consecutive days 1

Post-Procedure Enoxaparin Resumption

Low-Moderate Bleeding Risk Procedures:

• Resume enoxaparin 24 hours post-procedure at full therapeutic dose 2

High Bleeding Risk Procedures:

• Resume enoxaparin 48-72 hours post-procedure 2
• Consider prophylactic dosing (40 mg daily) for first 24-48 hours, then increase to therapeutic 2

Common Pitfalls to Avoid

1. Don't bridge low-risk patients - Studies show bridging increases bleeding without reducing thrombosis in CHA₂DS₂-VASc <6 and HAS-BLED >2 7

2. Don't stop enoxaparin too early - Must overlap minimum 5 days AND achieve therapeutic INR on two consecutive days 1

3. Don't use loading doses of acenocoumarol - Resume at maintenance dose to avoid supratherapeutic INR 2

4. Don't forget renal adjustment - Enoxaparin accumulates in renal failure; mandatory dose reduction 9

5. Don't give enoxaparin within 24 hours of neuraxial anesthesia - Risk of spinal hematoma 6

Special Populations

Cancer Patients:

• Prefer therapeutic LMWH throughout (dalteparin 200 IU/kg daily × 1 month, then 150 IU/kg daily) over bridging strategy 1, 9
• LMWH superior to warfarin/acenocoumarol for cancer-associated VTE 9

Mechanical Heart Valves:

• Mitral valve or older aortic valve models: Always bridge with therapeutic-dose enoxaparin 2
• Modern bileaflet aortic valve with no other risk factors: Consider no bridging 2